IL-1 blockade has been used in the treatment of MIS-C and KD, and recently anti-IL-1Ra autoantibodies have been described in over 60% of MIS-C patients while absent in healthy controls and patients with COVID-19 (33). Here, IL1B is linked to COVID-19–associated multisystem inflammatory syndrome in children.